Estrogen receptor modulators
Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
1. A method of treating breast cancer, comprising
identifying a subject that is in need of treatment for a breast cancer that is estrogen receptor alpha dependent and/or estrogen receptor alpha mediated; and
administering to said subject an effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof having the structure:
wherein:
A 1 is an optionally substituted aryl;
R 1 is an optionally substituted cycloalkyl;
R 2 and R 3 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C 1-6 alkyl and an optionally substituted C 1-6 haloalkyl; or R 2 and R 3 together with the carbon to which R 2 and R 3 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;
R 4 and R 5 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C 1-6 alkyl and an optionally substituted C 1-6 haloalkyl; or R 4 and R 5 together with the carbon to which R 4 and R 5 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;
R 6 , R 7 , R 8 and R 9 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted haloalkyl, an optionally substituted mono-substituted amine, and an optionally substituted di-substituted amine;
R 10 is hydrogen, deuterium, halogen, an optionally substituted alkyl, or an optionally substituted cycloalkyl;
R 11 is hydrogen or an optionally substituted C 1-6 alkyl; and
R 12 is hydrogen or C 1-3 alkyl.
2. The method of claim 1 , wherein said administering to said subject comprises an intravenous administration.
3. The method of claim 1 , wherein said administering to said subject comprises an oral administration.
4. The method of claim 1 , wherein said administering to said subject comprises an intramuscular administration.
5. The method of claim 1 , wherein said administering to said subject comprises a subcutaneous administration.
6. The method of claim 1 , wherein said administering to said subject comprises a topical administration.
7. The method of claim 1 , wherein R 11 is hydrogen.
8. The method of claim 1 , wherein A 1 is an optionally substituted phenyl.
9. The method of claim 8 , wherein A 1 is a substituted phenyl.
10. The method of claim 9 , wherein A 1 is a 3,5-difluorophenyl.
11. The method of claim 8 , wherein A 1 is an unsubstituted phenyl.
12. The method of claim 1 , wherein R 1 is an optionally substituted cycloalkyl selected from the group consisting of unsubstituted cyclobutyl, unsubstituted difluorocyclobutyl, unsubstituted cyclopentyl and unsubstituted bicyclopentyl.
13. The method of claim 1 , wherein R 1 is a substituted cycloalkyl.
14. The method of claim 12 , or a pharmaceutically acceptable salt thereof, wherein R 1 is an unsubstituted bicyclopentyl.
15. The method of claim 14 , wherein R 1 is an unsubstituted bicyclo[1.1.1]pentyl.
16. The method of claim 1 , wherein R 2 is selected from the group consisting of hydrogen, methyl, fluoromethyl and difluoromethyl.
17. The method of claim 1 , wherein any one or more of each of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 is hydrogen.
18. The method of claim 1 , wherein R 6 is hydroxy.
19. The method of claim 1 , wherein R 7 is selected from the group consisting of halogen, hydroxy, and unsubstituted alkoxy.
20. The method of claim 19 , wherein R 7 is fluoro or methoxy.
21. The method of claim 1 , wherein R 8 is hydroxy.
22. The method of claim 1 , wherein the compound of Formula (I) is selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.
23. The method of claim 1 , wherein the compound of Formula (I) is selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.
24. The method of claim 1 , wherein the compound of Formula (I) is selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.
25. The method of claim 1 , wherein the compound of Formula (I) is selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.
26. The method of claim 1 , wherein the compound of Formula (I) is formulated in a pharmaceutical composition that comprises a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.
27. A method of treating breast cancer, comprising
identifying a subject that is in need of treatment for a breast cancer that is estrogen receptor alpha dependent and/or estrogen receptor alpha mediated; and
administering to said subject an effective amount of a compound of Formula 11A, or a pharmaceutically acceptable salt thereof, having the structure:
28. The method of claim 27 , wherein said administering to said subject comprises an intravenous administration.
29. The method of claim 27 , wherein said administering to said subject comprises an oral administration.
30. The method of claim 27 , wherein said administering to said subject comprises an intramuscular administration.
31. The method of claim 27 , wherein said administering to said subject comprises a subcutaneous administration.
32. The method of claim 27 , wherein said administering to said subject comprises a topical administration.